Sotera Health (NASDAQ:SHC) Receives $16.50 Average PT from Analysts

Sotera Health (NASDAQ:SHC - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $16.50.

A number of analysts recently weighed in on the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $17.00 target price on shares of Sotera Health in a report on Tuesday, August 6th. Barclays raised their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, August 6th. Finally, Citigroup upped their price target on shares of Sotera Health from $18.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, November 6th.

Sotera Health Price Performance

Shares of Sotera Health stock traded down $0.33 during trading on Thursday, hitting $14.99. 699,840 shares of the company's stock traded hands, compared to its average volume of 1,295,643. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The firm's fifty day moving average price is $15.99 and its 200 day moving average price is $13.84. The company has a market cap of $4.25 billion, a PE ratio of 61.28 and a beta of 2.08. Sotera Health has a twelve month low of $10.71 and a twelve month high of $17.44.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. During the same quarter last year, the business posted $0.18 earnings per share. The business's quarterly revenue was up 8.5% compared to the same quarter last year. Analysts forecast that Sotera Health will post 0.61 earnings per share for the current year.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now owns 49,215,301 shares of the company's stock, valued at $739,705,974.03. The trade was a 16.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 55.12% of the stock is owned by company insiders.

Institutional Trading of Sotera Health

Hedge funds have recently added to or reduced their stakes in the stock. William Blair Investment Management LLC increased its position in Sotera Health by 0.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company's stock valued at $13,430,000 after purchasing an additional 6,707 shares during the period. Clearline Capital LP acquired a new position in Sotera Health in the second quarter valued at $1,707,000. First Pacific Advisors LP bought a new stake in Sotera Health during the second quarter valued at $540,000. Darsana Capital Partners LP acquired a new stake in Sotera Health during the 2nd quarter worth about $29,074,000. Finally, Bank of New York Mellon Corp raised its position in shares of Sotera Health by 3.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,004,046 shares of the company's stock worth $11,918,000 after acquiring an additional 37,681 shares in the last quarter. Institutional investors and hedge funds own 91.03% of the company's stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.